An opportunity to do well by doing good
Influenza spreads around the world in yearly outbreaks, resulting in about three to five million cases of severe illness and about 290,000 to 650,000 deaths worldwide. A vaccine that better prevents the high morbidity and mortality associated with this disease would represent a significant improvement in public health and a significant market opportunity. The influenza market alone is worth over $2 billion annually and is growing rapidly with vaccines that often work less than half of the time. The potential to revolutionize this market awaits the first company that can develop a vaccine with broader, more effective protection for all age groups.
FluGen’s value proposition is based on the idea that its lead vaccine candidate, M2SR will do just that. Extensive pre-clinical studies have shown that M2SR is not only more effective against matched flu strains, but can provide protection against drifted or mismatched strains as well. In addition, the company has completed two clinical studies and has initiated two additional studies to demonstrate these properties in patients.
FluGen raised $12 million in a Series A financing. Venture Investors LLC, the Wisconsin Alumni Research Foundation (WARF), the State of Wisconsin Investment Board, and other new investors participated in this first institutional financing of the company, along with many of FluGen’s existing investors led by Knox LLC. In addition, FluGen has secured over $30 million from the NIH and the Department of Defense.
We pride ourselves on our ability to exceed our investors’ expectations through:
- Strong leadership in the executive suite and on the Board of Directors
- Lean, semi-virtual operations and outstanding financial management
- Transparency and communication
To explore future investment opportunities in FluGen’s fast-tracking M2SR, contact President and CEO Paul Radspinner for more information.